Jul 19 2024 This Week in Cardiology

Jul 19, 2024

This podcast discusses vulnerable plaques and the scientific method, industry payments to trainees, comparison between tirzepatide and semaglutide, trial interpretation, and PFA. It also explores the use of PET imaging to detect vulnerable plaques, the impact of profit motives on medical advancements, and the significant cardiovascular benefits of semaglutide in treating heart disease.

Ask episode

Chapters

Transcript

Episode notes

Intro

00:00 • 5min

Analysis of PET Imaging Study on Vulnerable Plaques in Cardiology

04:42 • 5min

Exploring the Influence of Industry Payments on Cardiology Fellows

09:40 • 3min

Profit Motive in Healthcare and Treatment Comparison

12:12 • 2min

Discussion on Semaglutide, Terzepatide, Colchicine, and Pulse Field Ablation in Cardiology

14:38 • 11min

Vulnerable plaque and scientific method; industry payments to trainees; tirzepatide or semaglutide; trial interpretation; and PFA are the topics John Mandrola, MD, covers in today’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Non-invasive Imaging for Vulnerable Plaque

PET Imaging Finds Vulnerable Plaques That Cause MI

https://www.medscape.com/viewarticle/pet-imaging-finds-vulnerable-plaques-cause-mi-2024a1000cm2

JACC paper https://doi.org/10.1016/j.jacc.2024.03.419
Original JAMA-Card paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2806690

II. Industry Payments to Fellows

JAMA Network Letter https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2821267

III. GLP-1a Class Effect?

Semaglutide Significantly Improves Chronic Kidney Disease

https://www.medscape.com/viewarticle/semaglutide-significantly-improves-chronic-kidney-disease-2024a10009w9

Mounjaro Beats Ozempic, So Why Isn’t It More Popular?

https://www.medscape.com/viewarticle/mounjaro-beats-ozempic-so-why-isnt-it-more-popular-2024a1000ckd

JAMA-Internal Medicine: Semaglutide vs Tirzepatide https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080
SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
FLOW trial https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
SURPASS-CVOT – Rationale https://doi.org/10.1016/j.ahj.2023.09.007

IV. Colchicine and Trial Interpretation in the Lancet

CONVINCE https://doi.org/10.1016/S0140-6736(24)00968-1

V. PFA

Pulsed Field Ablation for AF: Are US Electrophysiologists Too Easily Impressed?

https://www.medscape.com/viewarticle/pulsed-field-ablation-af-are-us-electrophysiologists-too-2024a1000d2v

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net